Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 11 September, 2007

XTL Biopharm Ltd

Reminder: XTL to Hold Conf. Call Today at 8:30 ...


  Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the  
     Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic      
                               Neuropathic Pain                                

Valley Cottage, New York, September 11, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) will hold a conference call today,
September 11, 2007, at 8:30 a.m. EDT to discuss the Phase IIb clinical trial of
Bicifadine for the treatment of diabetic neuropathic pain that was initiated
yesterday.

Hosting the call will be Ron Bentsur, XTL's Chief Executive Officer.
Participating on the call will be two distinguished members of the diabetic
neuropathic pain clinical community: Dr. Christine Sang, Director of
Translational Pain Research at the Brigham and Women's Hospital, Harvard
Medical School, and Chair of XTL's Scientific Advisory Board; and Dr. Andrew
Boulton, Professor of Medicine at the Diabetes Research Institute, University
of Miami, and at the University of Manchester in the United Kingdom, Chair of
the American Diabetes Association Foot Care Interest Group, and a co-lead
investigator in the Bicifadine study.

In order to participate in the conference call, please call +1-877-502-9272 (in
the United States), +1-913-981-5581 (outside the United States), call in
passcode: 2040477. An audio recording of the conference call will be available
for replay by calling +1-888-203-1112 (in the United States), +1-719-457-0820
(outside the United States), replay passcode 2040477, for a period of 45 days
after the call.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is
developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for
the treatment of diabetic neuropathic pain. XTL is also developing several
novel pre-clinical hepatitis C small molecule inhibitors.  XTL also has an
active in-licensing and acquisition program designed to identify and acquire
additional drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur, Chief Executive Officer

Tel: +1-(845)-267-0707 ext. 225


                                                                                                                                                                                                                                              

a d v e r t i s e m e n t